PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed

References

• Roelcke U, Leenders KL. PET in neuro-oncology. J. Cancer Res. Clin. Oncol.127(1), 2–8 (2001).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol.64(6), 479–489 (2005).
   PubMed Web of Science ®Google Scholar
• Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin. Nucl. Med.33(2), 148–162 (2003).
   PubMedGoogle Scholar
• Miwa K, Shinoda J, Yano H et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J. Neurol. Neurosurg. Psychiatry75(10), 1457–1462 (2004).
   PubMed Web of Science ®Google Scholar
• Grosu AL, Weber WA, Astner ST et al.11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.66(2), 339–344 (2006).
   PubMedGoogle Scholar
• Kanai Y, Segawa H, Miyamoto K et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem.273(37), 23629–23632 (1998).
   PubMed Web of Science ®Google Scholar
• Langen KJ, Broer S. Molecular transport mechanisms of radiolabeled amino acids for PET and SPECT. J. Nucl. Med.45(9), 1435–1436 (2004).
   PubMedGoogle Scholar
• Langen KJ, Muhlensiepen H, Holschbach M et al. Transport mechanisms of 3-[123I]iodo-α-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl-L-methionine. J. Nucl. Med.41(7), 1250–1255 (2000).
   PubMed Web of Science ®Google Scholar
• Weber WA, Wester HJ, Grosu AL et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur. J. Nucl. Med.27(5), 542–549 (2000).
   PubMedGoogle Scholar
• Langen KJ, Jarosch M, Muhlensiepen H et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl. Med. Biol.30(5), 501–508 (2003).
   PubMedGoogle Scholar
• Pauleit D, Floeth F, Tellmann L et al. Comparison of O-(2–18F-fluoroethyl)-L-tyrosine PET and 3–123I-iodo-a-methyl-L-tyrosine SPECT in brain tumors. J. Nucl. Med.45(3), 374–381 (2004).
   PubMedGoogle Scholar
• Popperl G, Gotz C, Rachinger W et al. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur. J. Nucl. Med. Mol. Imaging31(11), 1464–1470 (2004).
   PubMedGoogle Scholar
• Goldman S, Levivier M, Pirotte B et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J. Nucl. Med.38(9), 1459–1462 (1997).
   PubMed Web of Science ®Google Scholar
• Pirotte B, Goldman S, David P et al. Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine. Acta Neurochir. Suppl.68, 133–138 (1997).
   PubMedGoogle Scholar
• Pirotte B, Goldman S, Dewitte O et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J. Neurosurg.104(2), 238–253 (2006).
   PubMedGoogle Scholar
• Voges J, Herholz K, Holzer T et al.11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact. Funct. Neurosurg.69(1–4 Pt 2), 129–135 (1997).
   PubMed Web of Science ®Google Scholar
• Tsuyuguchi N, Takami T, Sunada I et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery – in malignant glioma. Ann. Nucl. Med.18(4), 291–296 (2004).
   PubMed Web of Science ®Google Scholar
• Van Laere K, Ceyssens S, Van Calenbergh F et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur. J. Nucl. Med. Mol. Imaging32(1), 39–51 (2005).
   PubMed Web of Science ®Google Scholar
• Rachinger W, Goetz C, Popperl G et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery57(3), 505–511 (2005).
   PubMed Web of Science ®Google Scholar
• Nariai T, Tanaka Y, Wakimoto H et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J. Neurosurg.103(3), 498–507 (2005).
   PubMed Web of Science ®Google Scholar
• Wurker M, Herholz K, Voges J et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur. J. Nucl. Med.23(5), 583–586 (1996).
   PubMedGoogle Scholar
• Wyss M, Hofer S, Bruehlmeier M et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J. Neurooncol.95(1), 87–93 (2009).
   PubMed Web of Science ®Google Scholar
• Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain128(Pt 3), 678–687 (2005).
   PubMed Web of Science ®Google Scholar
• Herholz K, Holzer T, Bauer B et al.11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology50(5), 1316–1322 (1998).
   PubMed Web of Science ®Google Scholar
• Jacobs AH, Kracht LW, Gossmann A et al. Imaging in neurooncology. NeuroRx2(2), 333–347 (2005).
   PubMedGoogle Scholar
• Floeth FW, Pauleit D, Wittsack H-J et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J. Neurosurg.102(2), 318–327 (2005).
   PubMed Web of Science ®Google Scholar
• Levivier M, Goldman S, Pirotte B et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J. Neurosurg.82(3), 445–452 (1995).
   PubMed Web of Science ®Google Scholar
• Kracht LW, Miletic H, Busch S et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin. Cancer Res.10(21), 7163–7170 (2004).
   PubMed Web of Science ®Google Scholar
• Pirotte B, Goldman S, Massager N et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J. Nucl. Med.45(8), 1293–1298 (2004).
   PubMedGoogle Scholar
• Ogawa T, Shishido F, Kanno I et al. Cerebral glioma: evaluation with methionine PET. Radiology186(1), 45–53 (1993).
   PubMed Web of Science ®Google Scholar
• Nuutinen J, Sonninen P, Lehikoinen P et al. Radiotherapy treatment planning and long-term follow-up with [11C]methionine PET in patients with low-grade astrocytoma. Int. J. Radiat. Oncol. Biol. Phys.48(1), 43–52 (2000).
   PubMed Web of Science ®Google Scholar
• Popperl G, Goldbrunner R, Gildehaus FJ et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur. J. Nucl. Med. Mol. Imaging32(9), 1018–1025 (2005).
   PubMed Web of Science ®Google Scholar
• Popperl G, Gotz C, Rachinger W et al. Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur. J. Nucl. Med. Mol. Imaging33(7), 792–800 (2006).
   PubMed Web of Science ®Google Scholar
• Brock CS, Young H, O’Reilly SM et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the Phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br. J. Cancer82(3), 608–615 (2000).
   PubMed Web of Science ®Google Scholar
• De Witte O, Levivier M, Violon P et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery39(3), 470–476 (1996).
   PubMed Web of Science ®Google Scholar
• Ceyssens S, Van Laere K, de Groot T et al. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am. J. Neuroradiol.27(7), 1432–1437 (2006).
   PubMed Web of Science ®Google Scholar
• De Witte O, Goldberg I, Wikler D et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J. Neurosurg.95(5), 746–750 (2001).
   PubMed Web of Science ®Google Scholar
• Ribom D, Smits A. Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas. Neurol. Res.27(5), 516–521 (2005).
   PubMed Web of Science ®Google Scholar
• Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur. J. Nucl. Med. Mol. Imaging35(1), 65–71 (2008).
   PubMedGoogle Scholar
• Thiele F, Ehmer J, Piroth MD et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys. Med. Biol.54(18), 5525–5539 (2009).
   PubMed Web of Science ®Google Scholar
• Popperl G, Kreth FW, Herms J et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J. Nucl. Med.47(3), 393–403 (2006).
   PubMed Web of Science ®Google Scholar
• Popperl G, Kreth FW, Mehrkens JH et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur. J. Nucl. Med. Mol. Imaging34(12), 1933–1942 (2007).
   PubMed Web of Science ®Google Scholar
• Alavi JB, Alavi A, Chawluk J et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer62(6), 1074–1078 (1988).
   PubMed Web of Science ®Google Scholar
• Kim CK, Alavi JB, Alavi A, Reivich M. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J. Neurooncol.10(1), 85–91 (1991).
   PubMed Web of Science ®Google Scholar
• Barker FG, 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer79(1), 115–126 (1997).
   PubMed Web of Science ®Google Scholar
• Padma MV, Said S, Jacobs M et al. Prediction of pathology and survival by FDG PET in gliomas. J. Neurooncol.64(3), 227–237 (2003).
   PubMedGoogle Scholar
• Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J. Nucl. Med.45(11), 1851–1859 (2004).
   PubMedGoogle Scholar
• Choi SJ, Kim JS, Kim JH et al. [18F]3´-deoxy-3´-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur. J. Nucl. Med. Mol. Imaging32(6), 653–659 (2005).
   PubMed Web of Science ®Google Scholar
• Chen W, Cloughesy T, Kamdar N et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J. Nucl. Med.46(6), 945–952 (2005).
   PubMed Web of Science ®Google Scholar
• Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol.25(30), 4714–4721 (2007).
   PubMed Web of Science ®Google Scholar
• Beer AJ, Schwaiger M. Imaging of integrin αvβ3 expression. Cancer Metastasis Rev.27(4), 631–644 (2008).
   PubMed Web of Science ®Google Scholar
• Schnell O, Krebs B, Wagner E et al. Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol.18(3), 378–386 (2008).
   PubMed Web of Science ®Google Scholar
• Beer AJ, Haubner R, Sarbia M et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin. Cancer Res.12(13), 3942–3949 (2006).
   PubMed Web of Science ®Google Scholar
• Beer AJ, Grosu AL, Carlsen J et al. [18F]galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res.13(22 Pt 1), 6610–6616 (2007).
   PubMed Web of Science ®Google Scholar
• Haubner R, Weber WA, Beer AJ et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Med.2(3), e70 (2005).
   PubMed Web of Science ®Google Scholar
• Schnell O, Krebs B, Carlsen J et al. Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] galacto-RGD positron emission tomography. Neuro. Oncol.11(6), 861–870 (2009).
   PubMed Web of Science ®Google Scholar
• Judenhofer MS, Wehrl HF, Newport DF et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med.14(4), 459–465 (2008).
   PubMed Web of Science ®Google Scholar